All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MDS Alliance.

The MDS Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Should the telomerase inhibitor imetelstat become SoC in transfusion-dependent low-risk MDS?

Jan 12, 2021
Share:

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the MDS Hub spoke to Uwe Platzbecker, University of Leipzig Medical Center, Leipzig, DE. We asked, Should the telomerase inhibitor imetelstat become SoC in transfusion-dependent low-risk MDS?

In this video, Platzbecker reports the promising data, presented at ASH 2020, on the telomerase inhibitor imetelstat.

Should the telomerase inhibitor imetelstat become SoC in transfusion-dependent low-risk MDS?

 

Share: